SAGE241220C10000
- 0.10
- 0.000.00%
Sage Therapeutics Newsroom
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Agenus (AGEN) and SAGE Therapeutics (SAGE)
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $8 to $14
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $4 to $14
Truist Financial Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
RBC Upgrades SAGE Therapeutics to Sector Perform From Underperform, Keeps Speculative Risk, $4 Price Target
SAGE Therapeutics: Analyst Reiterates Sell Rating Amid Pipeline Setbacks and Prescriber Challenges
SAGE Therapeutics: Hold Rating Amid Dalzanemdor's Phase 2 Failure and Valuation Adjustments
Wedbush Cuts Price Target on SAGE Therapeutics to $4 From $7, Maintains Neutral Rating
Sage Therapeutics Analyst Ratings
SAGE Therapeutics: Hold Rating Amid Strategic Shift Following Dalzanemdor Discontinuation
CCORF Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $9
Morgan Stanley Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $9
Morgan Stanley Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Cuts Target Price to $9
SAGE Therapeutics: Balancing Promising Sales Growth With Strategic Uncertainties – A Hold Rating
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $10 to $26
Sage Therapeutics Price Target Cut to $8.00/Share From $9.00 by Oppenheimer
Sage Therapeutics Is Maintained at Perform by Oppenheimer
HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $14
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $4 to $26
Sage Therapeutics Analyst Ratings